3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Unknown
2
Active not recruiting
1
Sponsor Class
OTHER
16
OTHER_GOV
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Head & Neck
1
Breast
1
Conditions
Wounds and Injuries
1
Neoplasms
1
Head and Neck Neoplasms
1
Cancer Pain
1
Breast Neoplasms
1
Interventions
apatinib
25
Cisplatin
19
Capecitabine
17
Irinotecan
16
Cyclophosphamide
16
fludarabine
14
Radiotherapy
12
Oxaliplatin
12
Drug Therapy
12
camrelizumab
11
Paclitaxel
11
S 1 (combination)
10
Docetaxel
10
Carboplatin
10
Fluorouracil
9
Blood Specimen Collection
9
Bevacizumab
9
Nivolumab
8
tislelizumab
7
Radiation
7
Pemetrexed
7
Gemcitabine
7
Erlotinib Hydrochloride
7
Surgical Procedures, Operative
6
Neoadjuvant Therapy
6
Albumin-Bound Paclitaxel
6
toripalimab
5
anlotinib
5
XELOX
5
Tamoxifen
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
OTHER_GOV
×
Lidocaine
×
Clear all
NCT05800834
2023-09-28
MorphineGEL
Instituto Nacional de Cancer, Brazil
Phase 2
Unknown
106 enrolled
NCT04741880
2021-07-30
ELSA
Instituto Nacional de Cancer, Brazil
Phase 2/3
Unknown
66 enrolled